A Development of Nucleic Chromatin Measurements as a New Prognostic Marker for Severe Chronic Heart Failure

PLoS One. 2016 Feb 4;11(2):e0148209. doi: 10.1371/journal.pone.0148209. eCollection 2016.

Abstract

Background: Accurate prediction of both mortality and morbidity is of significant importance, but it is challenging in patients with severe heart failure. It is especially difficult to detect the optimal time for implanting mechanical circulatory support devices in such patients. We aimed to analyze the morphometric ultrastructure of nuclear chromatin in cardiomyocytes by developing an original clinical histopathological method. Using this method, we developed a biomarker to predict poor outcome in patients with dilated cardiomyopathy (DCM).

Methods and results: As a part of their diagnostic evaluation, 171 patients underwent endomyocardial biopsy (EMB). Of these, 63 patients diagnosed with DCM were included in this study. We used electron microscopic imaging of cardiomyocyte nuclei and an automated image analysis software program to assess whether it was possible to detect discontinuity of the nuclear periphery. Twelve months after EMB, all patients with a discontinuous nuclear periphery (Group A, n = 11) died from heart failure or underwent left ventricular assist device (VAD) implantation. In contrast, in patients with a continuous nuclear periphery (Group N, n = 52) only 7 patients (13%) underwent VAD implantation and there were no deaths (p<0.01). We then evaluated chromatin particle density (Nuc-CS) and chromatin thickness in the nuclear periphery (Per-CS) in Group N patients; these new parameters were able to identify patients with poor prognosis.

Conclusions: We developed novel morphometric methods based on cardiomyocyte nuclear chromatin that may provide pivotal information for early prediction of poor prognosis in patients with DCM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers
  • Biopsy
  • Cardiomyopathy, Dilated / diagnosis
  • Cardiomyopathy, Dilated / mortality*
  • Cardiomyopathy, Dilated / surgery
  • Cell Nucleus / pathology*
  • Chromatin / ultrastructure*
  • Electron Microscope Tomography
  • Female
  • Heart / physiopathology
  • Heart Failure / diagnosis
  • Heart Failure / mortality*
  • Heart Failure / surgery
  • Heart-Assist Devices
  • Humans
  • Male
  • Microscopy, Electron
  • Middle Aged
  • Myocytes, Cardiac / cytology*
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Biomarkers
  • Chromatin

Grants and funding

This work was supported by the Japanese Circulation Society Grant for Translational Research 2014 to Y. Sakata (http://www.j-circ.or.jp/translational_research/index.htm); the Ministry of Health, Labor, and Welfare-Japan to IK (http://www.mhlw.go.jp/english/); the Japan agency for medical research and development, Grant number 15Aek0109069h0002 to ST (http://www.amed.go.jp/); the Japan Society for the Promotion of Science, Grant numbers 24591097 and 15K09139 to YA (http://www.jsps.go.jp/english/); the Ministry of Education, Culture, Sports, Science, and Technology-Japan, Project numbers 26670402 to ST (http://www.mext.go.jp/english/); Japan Heart Foundation to YA (http://www.jhf.or.jp/english/); Japan Intractable Diseases Research Foundation to YA (http://www.nanbyou.or.jp/english/index.htm); Inoue Foundation for Science to YA (http://www.inoue-zaidan.or.jp/); Japan vascular disease research foundation to YA (http://www.disclo-koeki.org/02b/00412/); Takeda Science Foundation to YA (http://www.takeda-sci.or.jp/); Japan Foundation of Applied Enzymology to YA (https://www.jfae.or.jp/); Mochida Memorial Foundation to YA (http://www.mochida.co.jp/zaidan/); Banyu Foundation to YA (http://www.banyu-zaidan.or.jp/); Osaka Medical Research foundation for intractable diseases to YA (http://www.nanbyo.or.jp/zaidan/info2013.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.